Wainua.ca | Dosing & Administration

EN FR

WAINUA^®

Once-monthly WAINUA: 45 mg administered by subcutaneous
injection¹

Watch injection training video

Download injection video See transcript

Injection training is also available through the Connect360 Patient Support Program

Learn more

Dosing considerations¹

Treatment should be initiated by and remain under the supervision of a treating physician knowledgeable in the management of patients with amyloidosis.

Patients receiving WAINUA should take oral supplementation of the recommended daily allowance of vitamin A (approximately 3000 IU per day). Vitamin A supplementation should be continued throughout treatment. See monitoring recommendations below for more information.

The decision to continue treatment in patients whose disease progresses to FAP stage 3 polyneuropathy should be taken at the discretion of the physician based on the overall benefit and risk assessment. WAINUA is not indicated for the treatment of stage 3 disease.

Dose adjustments¹

No dose adjustment is necessary in: Geriatrics (patients 65 years or older) Patients with mild to moderate renal impairment (eGFR ≥45 to <90 mL/min/1.73 m²) Patients with mild hepatic impairment

WAINUA has not been studied in patients with eGFR <45 mL/min/1.73 m², end-stage renal disease, moderate or severe hepatic impairment, or prior liver transplant.

Administration¹

The autoinjector should be removed from refrigerated storage at least 30 minutes before use and should be allowed to reach room temperature prior to injection. Other warming methods should not be used.

Inspect WAINUA visually before use. The solution should appear colourless to yellow. Do not use if cloudiness, particulate matter, or discolouration is observed prior to administration.

Prior to initiation, patients and/or caregivers must be trained on proper preparation and administration of WAINUA. The first injection administered by the patient or caregiver should be performed under the guidance of an appropriately qualified healthcare professional.

If self-administered, WAINUA should be injected in the abdomen or upper thigh region. If a caregiver administers the injection, the back of the upper arm can also be used. Do not inject into scar tissue or areas that are reddened, inflamed, or swollen.

In addition to the injection training video, comprehensive administration instructions are available for patients and/or caregivers in the Patient Medication Information for WAINUA.¹

Download

Monitoring recommendations¹

Laboratory tests for serum vitamin A should not be used to guide vitamin A supplementation during treatment with WAINUA, as they do not reflect the total amount of vitamin A in the body. This is because transport and tissue uptake of vitamin A can occur through alternative mechanisms in the absence of retinol binding protein.

Patients or caregivers may administer WAINUA after proper training, with medical follow-up as necessary. See the WAINUA Product Monograph for complete dosing and administration instructions.

eGFR: estimated glomerular filtration rate; FAP: familial amyloid polyneuropathy.

* Clinical significance unknown.

† Comparative clinical significance has not been established.

References: 1. WAINUA® Product Monograph. AstraZeneca Canada Inc. August 26, 2025. 2. Data on file. AstraZeneca Canada Inc. August 2024.

WAINUA^®

Recommended Dosing & Administration

Once-monthly WAINUA: 45 mg administered by subcutaneous
injection¹

WAINUA is the FIRST AND ONLY TTR silencer available for once-monthly self-injection with an autoinjector^1,2*^†

Watch injection training video

Dosing considerations¹

Dose adjustments¹

Administration¹

Monitoring recommendations¹

WAINUA® Important Safety Information

WAINUA®

Recommended Dosing & Administration

Once-monthly WAINUA: 45 mg administered by subcutaneous injection1

WAINUA is the FIRST AND ONLY TTR silencer available for once-monthly self-injection with an autoinjector1,2*†

Watch injection training video

Dosing considerations1

Dose adjustments1

Administration1

Monitoring recommendations1

AZ Reg Popup

Sign up for AstraZeneca mail

WAINUA^® Important Safety Information

WAINUA^®

Once-monthly WAINUA: 45 mg administered by subcutaneous
injection¹

WAINUA is the FIRST AND ONLY TTR silencer available for once-monthly self-injection with an autoinjector^1,2*^†

Dosing considerations¹

Dose adjustments¹

Administration¹

Monitoring recommendations¹